A major advantage of our study over initial treatment studies is that we leverage these findings by using the B16F10 in C57BL6 mice to demonstrate TXNRD1 inhibitors are sufficient in augmenting Treg frequencies and tumor burden without other interventions. The gene discussed is TXNRD1; the disease is neoplasm.